Profile data is unavailable for this security.
About the company
Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.
- Revenue in USD (TTM)46.74m
- Net income in USD-166.98m
- Incorporated2022
- Employees105.00
- LocationScilex Holding Co960 San Antonio RoadPALO ALTO 94303United StatesUSA
- Phone+1 (650) 516-4310
- Fax+1 (302) 636-5454
- Websitehttps://www.scilexholding.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc | 9.94m | -164.57m | 134.71m | 68.00 | -- | 8.00 | -- | 13.56 | -5.77 | -5.77 | 0.3508 | 0.63 | 0.0482 | -- | 11.73 | 146,102.90 | -79.76 | -54.44 | -95.35 | -64.32 | -- | -- | -1,656.51 | -772.82 | -- | -- | 0.7122 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 134.86m | 53.00 | 8.68 | 2.91 | 7.98 | 2.85 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Repare Therapeutics Inc | 51.13m | -93.80m | 134.98m | 179.00 | -- | 0.6364 | -- | 2.64 | -2.23 | -2.23 | 1.21 | 5.03 | 0.1655 | -- | 5.21 | 285,659.20 | -30.36 | -23.40 | -37.50 | -26.37 | -- | -- | -183.44 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 138.02m | 143.00 | -- | 0.4272 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| P3 Health Partners Inc | 1.27bn | -57.77m | 140.96m | 400.00 | -- | 0.366 | -- | 0.1113 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| CytoDyn Inc | 0.00 | -51.69m | 142.05m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| I-Mab ADR | 3.81m | -202.27m | 145.12m | 318.00 | -- | 0.612 | -- | 38.04 | -2.28 | -2.28 | 0.0444 | 2.94 | 0.0083 | -- | -- | -- | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -- | -- |
| Scilex Holding Co | 46.74m | -166.98m | 146.33m | 105.00 | -- | -- | -- | 3.13 | -1.25 | -1.25 | 0.3587 | -1.73 | 0.4977 | 5.61 | 1.67 | 445,171.40 | -121.73 | -- | -- | -- | 66.45 | -- | -244.59 | -- | 0.17 | -11.86 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Biostem Technologies Inc | -100.00bn | -100.00bn | 147.63m | 67.00 | -- | -- | -- | -- | -- | -- | -- | -0.2692 | -- | -- | -- | -- | -- | -107.46 | -- | -- | -- | 59.17 | -- | -120.14 | 0.4177 | -- | 2.41 | -- | 72.14 | 47.77 | 42.48 | -- | -- | -- |
| Gossamer Bio Inc | 0.00 | -179.82m | 150.69m | 135.00 | -- | 2.40 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | -62.57m | 154.75m | -- | -- | -- | -- | -- | -0.4043 | -0.4043 | 0.00 | -0.5867 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.74 | 42.99 | -- | -- | -- | -41.32 | -- | -- | -- |
| ProQR Therapeutics NV | 10.18m | -30.06m | 157.28m | 157.00 | -- | 3.68 | -- | 15.44 | -0.3712 | -0.3712 | 0.1257 | 0.5253 | 0.0616 | -- | 0.332 | 64,866.98 | -17.94 | -35.51 | -21.82 | -40.51 | -- | -- | -291.18 | -926.31 | -- | -- | 0.3229 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Achieve Life Sciences Inc | 0.00 | -29.82m | 157.90m | 22.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | -0.0684 | 0.00 | -- | -- | 0.00 | -120.85 | -86.31 | -860.46 | -119.59 | -- | -- | -- | -- | -- | -10.66 | 1.10 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Regulus Therapeutics Inc | 0.00 | -30.04m | 158.43m | 30.00 | -- | 2.31 | -- | -- | -1.59 | -1.59 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -77.55 | -53.74 | -104.84 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.0592 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Data as of Apr 26 2024. Currency figures normalised to Scilex Holding Co's reporting currency: US Dollar USD
12.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 7.40m | 4.45% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.54m | 3.33% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.90m | 2.35% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.00m | 0.60% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 681.01k | 0.41% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 627.04k | 0.38% |
| Rafferty Asset Management LLCas of 31 Dec 2023 | 620.13k | 0.37% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 580.20k | 0.35% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 477.62k | 0.29% |
| Hudson Bay Capital Management LPas of 31 Dec 2023 | 424.68k | 0.26% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
